[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Questions and Answers
Ortho Evra (norelgestromin/ethinyl estradiol)

For current questions and answers on Ortho Evra, please see http://www.fda.gov/cder/drug/infopage/orthoevra/default.htm

1.  What is FDA announcing today?

FDA is announcing a revision to the label for the drug Ortho Evra, the only skin patch approved for birth control.  This change includes a new bolded warning about higher exposure to estrogen for women using the weekly patch compared to taking a daily birth control pill containing 35 micrograms of estrogen, a commonly prescribed dose.  Higher levels of estrogen may put some women at increased risk for getting blood clots. When thinking about prescribing or using  Ortho Evra, healthcare professionals and women need to balance the increased exposure to estrogen against  the chance of pregnancy if a birth control pill is not taken daily.

2.  Why is the FDA making this announcement?

A woman on Ortho Evra may be exposed to approximately 60% more estrogen than if she were taking a typical 35 microgram estrogen birth control pill. There are also high dose estrogen pills on the market, such as the 50 microgram birth control pills, and some women need these.  Estrogen use is linked to blood clots in the legs and lungs and other clotting problems such as strokes and heart attacks.  It is not known if women using Ortho Evra have a higher risk of serious side effects  than women taking the typical 35 microgram estrogen pills.  

3.  How does the increase in exposure of estrogen affect me when taking Ortho Evra?

In general, a woman may be at higher risk for getting side effects  if she takes higher doses of estrogen.  However, it is not known if a woman using the Ortho Evra patch is at higher risk for serious side effects than if she is using a typical birth control pill.  Women should discuss with their health care professional whether the Ortho Evra patch is a good method of contraception for them.

4. Can a woman decrease the amount of estrogen from the Ortho Evra patch by cutting the patch and applying only a part of the patch?

No.  The patch should not be cut.  If cut or altered, Ortho Evra will not protect against pregnancy.

5. If a woman wants to change from the Ortho Evra patch to a birth control pill, what should she do?

Talk to her health care professional.  The health care professional will help her make this change.

6.  Where can I find more information on this?

If you have further questions regarding any medications, please contact the Center for Drug’s Division of Drug Information at: 888-INFO-FDA (888-463-6332), or email us at:  druginfo@fda.hhs.gov.

Back to Top     Back to Ortho Evra

Date created: November 10, 2005, updated September 20, 2006

horizonal rule